Professor Michael Hofman is a nuclear medicine physician in the Centre for Cancer Imaging at the Peter MacCallum Cancer in Melbourne. He has a broad interest inpositron emission tomography (PET), molecular imaging applications in oncology and radionuclide therapy.
Professor Hofman has a vision of improving patient outcomes by using molecular imaging to non-invasively characterise disease thereby enabling improved selection of the most appropriate therapy for an individual patient and better assessment of therapeutic response. He has particular interest in novel PET radiotracers, including F-18 and Ga-68, and theranostic applications including neuroendocrine and prostate cancers. Currently, he is the principal investigator of a randomised multi-centre trial of PSMA PET/CT in PET/CT, a prospective trial of Lu-177 PSMA therapy and a propsective trial investigating the role of PET V/Q scanning in patients with lung cancer.
Professor Hofman previously completed a clinical and research fellowship at Guys and St Thomas in London. He is a fellow of the Inernational Cancer Imaging Society (ICIS) and serves on the editoral board of Cancer Imaging, Leukaemia Lymphoma and the Journal of Medical Imaging and Radiation Oncology (JMIRO). He is an inaugral scientific member of the Australasian Radiopharmaceutical Trials Network (ARTnet).
IN THE NEWS
Australian-first trial set to revolutionalise treatment of advanced prostate cancer, Prostate Cancer Foundation of Australia
New trial for prostate cancer patients, Seven News
Nuclear medicine could be a game changer for advanced prostate cancer, Australian Financial Review
2016: Cum Laude Award at RSNA for best Molecular Imaging Educational Exhibit
2015: Fellow of the International Cancer Imaging Society (ICIS)
2015: ANSTO Award, Australian and New Zealand Society of Nuclear Medicine for significant innovation in research or clinical practice in the field of Nuclear Medicine
2014: Henry Wagner Award 2014 for best oral scientific presentation at the World Federation in Nuclear Medicine and Biology World Federation in Nuclear Medicine and Biology scientific meeting
2013: Roentogen Society of North America (RSNA) Cum Laude Award 2013 for the top 5% ranked educational exhibits
2011: ANSTO Award, Australian and New Zealand Society of Nuclear Medicine
2011: Eckert & Ziegler Abstract Award for top 5 ranking scientific abtracts at the European Association of Nuclear Medicine scentific meeting, Birmingham
2011: Jan Esser Science Award for the Best Oral Presentation, World Federation in Nuclear Medicine and Biology, Cape Town